Diabetes and tuberculosis: A review of the role of optimal glycemic control

Journal of Diabetes and Metabolic Disorders

Volumn 11, Issue 1, 2012, Pages

  Niazi, Asfandyar K ^a   Kalra, Sanjay ^b  

^a SHIFA COLLEGE OF MEDICINE   (Pakistan)

^b Bharti Hospital and Bharti Research Institute of Diabetes and Endocrinology   (India)

Author keywords

Anti tubercular treatment; Epidemic; Glycemic control; Insulin; Oral hypoglycemic drugs

Indexed keywords

BIGUANIDE; INSULIN; INSULIN ASPART; INSULIN LISPRO; ISONIAZID; PYRIDOXINE; RIFAMPICIN; SULFONYLUREA; ORAL ANTIDIABETIC AGENT;

CELLULAR IMMUNITY; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE EXACERBATION; DISEASE PREDISPOSITION; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; GLUCOSE TOLERANCE; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; INCIDENCE; INSULIN TREATMENT; KETONURIA; NEUTROPHIL COUNT; REVIEW; RISK FACTOR; SIDE EFFECT; TUBERCULOSIS; DRUG CONTRAINDICATION; MANAGED CARE; PATHOPHYSIOLOGY;

EID: 84885337634     PISSN: None     EISSN: 22516581     Source Type: Journal    
DOI: 10.1186/2251-6581-11-28     Document Type: Review

References (32)

1. Morton R. Phthisiolgia: or a treatise of consumptions 1694, London: Smith and Walford.
2. Rajalakshmi S, Veluchamy G. Yugi's pramegam and diabetes mellitus: an analogue. Bull Indian Inst Hist Med Hyderabad. 1999, 29(1):83-7.
3. West KM. Epidemiology of diabetes and its vascular lesions 1978, 351. New York: Elsevier.
4. Tattersall RB, Gale EAM. Infections. Diabetes, clinical management 1990, 358-364. Edinburgh: Churchill Livingstone, Tattersall RB, Gale EAM.
5. Wilson RM. Infection and diabetes mellitus. Textbook of diabetes 1991, 813-9. Oxford: Blackwell Scientific Publication, Pickup JC, Williams G.
6. Ruslami R, Aarnoutse RE, Alisjahbana B, Van Der Ven AJAM, Van Crevel R. Implications of the global increase of diabetes for tuberculosis control and patient care. Trop Med & Int Health 2010, 15:1289-1299. 10.1111/j.1365-3156.2010.02625.x, 23241184.
7. Nijland HMJ, Ruslami R, Stalenhoef JE, Nelwan EJ, Alisjahbana B, Nelwan RHH, et al. Exposure to rifampicin is strongly reduced in patients with tuberculosis and type 2 diabetes. Clin Infect Dis 2006, 43(7):848-854. 10.1086/507543, 16941365.
8. Winterbauer R, Bedon G, Ball W. Recurrent Pneumonia: Predisposing illness and clinical pattern of 158 patients. Ann Intern Med 1969, 70:689.
9. Stevenson CR, Critchley JA, Forouhi NG, Roglic G, Williams BG, Dye C, et al. Diabetes and the risk of tuberculosis: a neglected threat to public health?. Chronic Illn 2007, 3:228-45. 10.1177/1742395307081502, 18083679.
10. Restrepo BI. Convergence of the tuberculosis and diabetes epidemics: Renewal of old acquaintances. Clin Infect Dis 2007, 45(4):436-438. 10.1086/519939, 2900315, 17638190.
11. Jeon C, Murray M. Diabetes mellitus increases the risk of active tuberculosis: A systematic review of 13 observational studies. PLoS Med 2008, 5:e152. 10.1371/journal.pmed.0050152, 2459204, 18630984.
12. Alisjahbana B, Sahiratmadja E, Nelwan EJ, Purva AM, Ahmad Y, Ottenhoff TH, et al. The effect of type 2 diabetes mellitus on the presentation and treatment response of pulmonary tuberculosis. Clin Infect Dis 2007, 45:428-35. 10.1086/519841, 17638189.
13. Swai AB, McLarty DG, Mugusi F. Tuberculosis in diabetic patients in Tanzania. Trop Doct. 1990, 20(4):147-50.
14. Alisjahbana B, Sahiratmadja E, Nelwan EJ, Purwa AM, Ahmad Y, Ottenhoff THM, et al. The effect of diabetes mellitus on the presentation and treatment response of pulmonary tuberculosis. Clin Infect Dis 2007, 45(4):428-435. 10.1086/519841, 17638189.
15. Englebach K. Passagerer diabetes mellitus bei 2 Tuberkulosekranken [Transitory diabetes mellitus in two tuberculotics.]. J Beitr Klin Tuberk Spezif Tuberkuloseforsch 1954, 110:470-3.
16. Nichols GP. Diabetes among young tuberculous patients; a review of the association of the two diseases. Am Rev Tuberc 1957, 76:1016-30.
17. Mugusi F, Swai A, Alberti K, Melarty G. Increased prevalence of diabetes mellitus in patients with pulmonary tuberculosis in Tanzania. Tubercle 1990, 71:271-6. 10.1016/0041-3879(90)90040-F, 2267680.
18. Jeon CY, Harries AD, Baker MA, Hart JE, Kapur A, Lönnroth K, et al. Bi-directional screening for tuberculosis and diabetes: a systematic review. Trop Med Int Health 2010, 15:1300-1314. 10.1111/j.1365-3156.2010.02632.x, 20958887.
19. Guptan A, Shah A. Tuberculosis and diabetes: an appraisal. Ind J Tub 2000, 47(3):2-8.
20. Geevarghese PJ. Pancreatic diabetes 1967, 26-28. Popular Prakashan: Bombay.
21. Geerlings SC, Hopelman AI. Immune dysfunction in patients with diabetes mellitus (DM). FEMS Immunol Med Microbiol 1999, 26:259-65. 10.1111/j.1574-695X.1999.tb01397.x, 10575137.
22. Tsukaguchi K, Yoneda T, Yoshikawa M. Case study of interleukin-1 beta, tumor necrosis factor alpha and interleukin-6 production by peripheral blood monocytes in patients with diabetes mellitus complicated by pulmonary tuberculosis. Kekkaku 1992, 67:755-60.
23. Sidibe EH, Sankale M. Diabetes and pulmonary tuberculosis: epidemiology, pathophysiology and symptomatology. J French Stud Res Health 2007, 17(1):29-32.
24. Rodbard HW, Jelleinger PS, Davidson JA, et al. Statement by an AACE/ACE Consensus Panel on type 2 diabetes mellitus An algorithm for glycemic control. Endocrine Practice 2009, 15(6):540-559.
25. Kalra S, Kalra B, Sharma A. Ketonuria and ketonemia in type 2 diabetes mellitus patients attending an Indian endocrine clinic. Ind J Endocr & Metab 2007, 11(3-4):7-10.
26. Kalra S, Kalra B, Nanda G. OPD management of ketosis in pregnancy: aspart vs. regular insulin. Diabetic Med 2006, 23(4):504.
27. Kalra S. Walking the tightrope in critical care: role of rapid-acting analogue insulin. Medicine Update 2009 (Vol 19 Part I) 2009, 388-394. New Delh: Jay Pee Bros, Agarwal AK, 19.
28. Kalra S, Kalra B, Sharma A, Chhabra B. Dosage frequency of premixed aspart insulin: clinical correlates of three-dose. Diabetes 2008, 57(1):570.
29. Rao PV. Persons with type 2 diabetes and co-morbid active tuberculosis should be treated with insulin. Int J Diab Dev Countries 1999, 19:79-86.
30. Atkin SL, Masson EA, Bodmer CW, Walker BA, White MC. Increased insulin requirement in a patient with Type 1 diabetes on rifampicin [letter]. Diabet Med 1993, 10:392. 10.1111/j.1464-5491.1993.tb00086.x, 8508626.
31. Lebovitz HE. Oral hypoglycemic agents 1990, 554-574. Ellenberg and Rifkins's diabetes mellitus, theory and practice. 4th ed. New York: Elsevier: Rifkin H, Porte Jr D, eds.
32. Madsbad S. Treatment of type 2 diabetes with incretin-based therapies. Lancet 2009, 373(9662):438-439. 10.1016/S0140-6736(08)61247-7, 18819704.